Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company dedicated to the advent of optical biopsy. The company researches, develops and markets innovative tools to visualize and detect cellular abnormalities during endoscopic procedures. Its flagship product, Cellvizio®, a probe-­based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-­resolution cellular views of tissue inside the body. Large, international, multi-center clinical trials have demonstrated Cellvizio's ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-­‐Mark for use in the GI tract, biliary and pancreatic ducts and lungs.
Paris, FR
83 (est)

Mauna Kea Technologies Locations

Paris, FR
Cambridge, US

Mauna Kea Technologies Metrics

Mauna Kea Technologies Summary

Founding Date


Market capitalization

€54.3 M

Closing share price


Mauna Kea Technologies Market Value History

Mauna Kea Technologies News